China Emerges as a New Hub for Global Medical Tourism

The surge in medical tourism is underpinned by aggressive policy reforms and rapid clinical innovation. China currently offers 240-hour visa-free transit for citizens from 57 countries, simplifying entry for those seeking localized treatments. These institutional changes coincide with the country’s growing clinical influence, as it now accounts for 33.7% of all drugs currently in global development.

Technological breakthroughs act as the primary catalyst for this influx. In June 2026, China authorized the world's first CAR-T therapy for solid tumors, drawing patients from abroad who cannot access the treatment elsewhere. Jiahui Health has already treated its first international recipient of this therapy, a New Zealand national with advanced gastric cancer. Similarly, patients from the United States are traveling to Shanghai to access ivonescimab, a bispecific antibody therapy currently exclusive to the Chinese market.

Shanghai is emerging as the central gateway for these cross-border medical services. Jiahui Health reported over 100,000 international outpatient visits last year, supported by infrastructure that includes direct billing with overseas insurers and multilingual coordination teams. Looking forward, the focus remains on standardizing regulatory dialogues regarding telemedicine and health data to solidify China’s trajectory toward becoming a top-tier destination for international medical care within the next five years.